for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cansino Biologics Inc

6185.HK

Latest Trade

420.00HKD

Change

51.20(+13.88%)

Volume

3,425,733

Today's Range

373.00

 - 

437.00

52 Week Range

141.10

 - 

450.00

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
368.80
Open
373.00
Volume
3,425,733
3M AVG Volume
33.35
Today's High
437.00
Today's Low
373.00
52 Week High
450.00
52 Week Low
141.10
Shares Out (MIL)
264.17
Market Cap (MIL)
142,389.00
Forward P/E
13.07
Dividend (Yield %)
--

Next Event

Q2 2021 CanSino Biologics Inc Earnings Release

Latest Developments

更多

Cansino Biologics Says Intends To Include Class I, II Medical Device Sales To Business Scope

JPMorgan Chase & Co's Long Position In CanSino Biologics Falls To 3.44% - HKEX Filing

JPMorgan Chase & Co's Long Position In CanSino Biologics Rises To 9.25% - HKEX Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cansino Biologics Inc

CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Industry

Biotechnology & Drugs

Contact Info

+86.22.58213766

http://www.cansinotech.com.cn/

Executive Leadership

Xuefeng Yu

Executive Chairman of the Board, Chief Executive Officer, General Manager

Jing Wang

Chief Financial Officer, Secretary of the Board

Shou Bai Chao

Chief Operating Officer, Deputy General Manager, Executive Director

Dongxu Qiu

Executive Vice President, Deputy General Manager, Executive Director

Huihua Mao

Executive Vice President, Deputy General Manager

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2019

0.0K

2020

0.0K

2021(E)

18.0K
EPS (CNY)

2019

-0.770

2020

-1.720

2021(E)

27.284
Price To Earnings (TTM)
--
Price To Sales (TTM)
6,393.99
Price To Book (MRQ)
12.52
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2.35
LT Debt To Equity (MRQ)
1.54
Return on Investment (TTM)
-9.92
Return on Equity (TTM)
-9.30

Latest News

Latest News

Chinese researchers to test double doses of CanSino's coronavirus vaccine candidate

Researchers plan to start a clinical trial for an additional dose of a coronavirus vaccine candidate co-developed by China's CanSino Biologics Inc and a military-backed research unit, clinical trial registry data showed.

UPDATE 1-China's CanSino defends coronavirus vaccine candidate after experts cast doubt

China's CanSino Biologics Inc said on Wednesday that expert opinion on its high-profile coronavirus vaccine candidate should not be followed "blindly" without sufficient clinical trial data.

China's CanSino defends coronavirus vaccine candidate after experts cast doubt

China's CanSino Biologics Inc said on Wednesday expert opinion on its high-profile coronavirus vaccine candidate should not be followed "blindly" without sufficient clinical trial data.

UPDATE 1-Chinese vaccine maker's coronavirus program with Canada ends

Canada's National Research Council (NRC) said on Wednesday that it has ended its partnership for a coronavirus vaccine with CanSino Biologics, saying the Chinese company lacks the authority to ship the vaccine at this time.

CanSino blames Chinese officials for failure of joint vaccine program with Canada - Globe and Mail

Chinese vaccine-maker CanSino Biologics said on Tuesday domestic bureaucratic indecision was the reason behind the failure of a coronavirus vaccine partnership with Canada, the Globe and Mail reported, citing the company's chief executive officer. CanSino in May had agreed...

UPDATE 1-Testing of CanSino's COVID-19 candidate vaccine begins in Russia

Russia's Petrovax has started a late-stage trial of a COVID-19 candidate vaccine from CanSino Biologics Inc in the country, records show, as the Chinese drug firm steps up testing abroad to close in on regulatory approval.

Testing of CanSino's COVID-19 candidate vaccine begins in Russia

A late-stage trial of a COVID-19 candidate vaccine from CanSino Biologics Inc has started in Russia, registration records showed, as the Chinese pharmaceutical firm steps up testing abroad to close in on regulatory approval.

China grants country's first COVID-19 vaccine patent to CanSino -state media

China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country's intellectual property regulator.

CanSino to start Phase III trial of COVID-19 vaccine in Saudi

Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China's CanSino Biologics Inc, a Saudi health ministry spokesman said on Sunday.

CanSino COVID-19 vaccine shows immune response in human trial

A COVID-19 vaccine developed by CanSino Biologics Inc and China's military research unit has shown to be safe and induced immune response in most of the recipients who got one shot, researchers said on Monday.

CORRECTED-China's CanSino in talks for COVID-19 vaccine Phase III trial overseas

Chinese vaccine developer CanSino Biologics is in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental COVID-19 vaccine, its co-founder said on Saturday.

UPDATE 1-Chinese coronavirus vaccine could be tested, manufactured in Canada

China's CanSino Biologics Inc , the company behind one of the few coronavirus vaccine candidates already in clinical trials, is collaborating with Canada's National Research Council to "pave the way" for future trials in Canada, the research council said on Tuesday.

Chinese coronavirus vaccine could be tested, manufactured in Canada

China's CanSino Biologics Inc , the company behind one of the few coronavirus vaccine candidates already in clinical trials, is collaborating with Canada's National Research Council to "pave the way" for future trials in Canada, the research council said on Tuesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up